Cargando…

Structural Implications for Selective Targeting of PARPs

Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that use NAD(+) as a substrate to synthesize polymers of ADP-ribose (PAR) as post-translational modifications of proteins. PARPs have important cellular roles that include preserving genomic integrity, telomere maintenance, transcriptional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steffen, Jamin D., Brody, Jonathan R., Armen, Roger S., Pascal, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868897/ https://www.ncbi.nlm.nih.gov/pubmed/24392349 http://dx.doi.org/10.3389/fonc.2013.00301

Ejemplares similares

Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage
por: Steffen, Jamin D., et al.
Publicado: (2016)

Editorial: Inhibiting PARP as a Strategic Target in Cancer
por: Zorn, Kristin K., et al.
Publicado: (2016)

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
por: Shah, Girish M., et al.
Publicado: (2013)

β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation
por: Zhao, Wenxiu, et al.
Publicado: (2021)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
por: Langelier, Marie-France, et al.
Publicado: (2014)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Effectiveness of PARP inhibition in enhancing the radiosensitivity of 3D spheroids of head and neck squamous cell carcinoma
por: Zhou, Chumin, et al.
Publicado: (2022)

Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
por: Weaver, Alice N., et al.
Publicado: (2013)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
por: Vikas, Praveen, et al.
Publicado: (2020)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer
por: Bian, Xing, et al.
Publicado: (2020)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer
por: Bian, Xing, et al.
Publicado: (2023)

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

Chloroquine Triggers Cell Death and Inhibits PARPs in Cell Models of Aggressive Hepatoblastoma
por: Eloranta, Katja, et al.
Publicado: (2020)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

PARP inhibitor-related haemorrhages: What does the real-world study say?
por: Wang, Shiyan, et al.
Publicado: (2023)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
por: De Lorenzo, Silvana B., et al.
Publicado: (2013)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance
por: Uddin, Mohammed Hafiz, et al.
Publicado: (2022)

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
por: Gupta, Shiv K., et al.
Publicado: (2019)

Overview of Cancer Control in Armenia and Policy Implications
por: Bedirian, Karen, et al.
Publicado: (2022)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma
por: Sabbatino, Francesco, et al.
Publicado: (2020)

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Wang, Yizi, et al.
Publicado: (2020)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
por: Bian, Yuan, et al.
Publicado: (2022)

3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction
por: Zhang, Huan, et al.
Publicado: (2022)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_36p5782cj5pei73l7t4us7b1p8